[Risk-adapted early detection program for prostate cancer 2.0-position paper of the German Society of Urology 2024]. / Risikoadaptierte Prostatakarzinomfrüherkennung 2.0 Positionspapier der Deutschen Gesellschaft für Urologie 2024.
Urologie
; 63(9): 893-898, 2024 Sep.
Article
em De
| MEDLINE
| ID: mdl-39134785
ABSTRACT
BACKGROUND AND OBJECTIVE:
Despite the proven effectiveness of organized PSA-based screening in reducing prostate cancer-related mortality, there is currently no program in Germany covered by statutory health insurance. In accordance with the EU Council Decision (2022/0290(NLE)), the German Society of Urology (DGU) has developed a concept for risk-adapted prostate cancer early detection. MATERIALS ANDMETHODS:
Based on a literature review of current screening studies, an algorithm for PSA-based prostate cancer early detection was developed.RESULTS:
Risk-adapted prostate cancer screening involves PSA testing in the age group of 45-70 years, followed by PSA-based individual risk stratification and stepwise expansion of diagnostics through magnetic resonance imaging (MRI) to biopsy. While initially up to 2.6 million men will undergo PSA testing, a reduction in these initial examinations to fewer than 200,000 men per year will occur from year four onwards.CONCLUSIONS:
The presented algorithm provides clear recommendations for risk-adapted PSA-based early detection for prostate cancer for urologists and patients. The goal is to improve diagnosis of clinically significant prostate cancer, while reducing overdiagnosis and overtreatment.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Algoritmos
/
Antígeno Prostático Específico
/
Detecção Precoce de Câncer
Limite:
Aged
/
Humans
/
Male
/
Middle aged
País como assunto:
Europa
Idioma:
De
Ano de publicação:
2024
Tipo de documento:
Article